Published in Proc Natl Acad Sci U S A on September 01, 1993
Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas. Neurol Sci (2011) 1.39
Role of neurotrophins and neurotrophins receptors in the in vitro invasion and heparanase production of human prostate cancer cells. Clin Exp Metastasis (1999) 0.91
Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci U S A (1998) 0.91
NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association. Oncogene (2009) 0.89
Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells. J Cancer Res Clin Oncol (1997) 0.83
Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Br J Cancer (1995) 0.79
Expression of Growth Factors in Normal and Neoplastic Pituitary Tissues. Endocr Pathol (2000) 0.76
Nerve growth factor: role in growth, differentiation and controlling cancer cell development. J Exp Clin Cancer Res (2016) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A (1976) 21.06
The nerve growth factor 35 years later. Science (1987) 7.25
Physiology of nerve growth factor. Physiol Rev (1980) 4.58
The trk proto-oncogene encodes a receptor for nerve growth factor. Cell (1991) 4.54
High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature (1991) 4.44
The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science (1991) 3.86
Expression and structure of the human NGF receptor. Cell (1986) 3.82
Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol (1989) 3.10
Gene transfer and molecular cloning of the rat nerve growth factor receptor. Nature (1987) 2.98
The nerve growth factor: biochemistry, synthesis, and mechanism of action. Annu Rev Neurosci (1980) 2.61
The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell (1991) 2.56
trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell (1991) 2.31
A monoclonal antibody modulates the interaction of nerve growth factor with PC12 cells. J Biol Chem (1984) 1.88
Dopamine: a prolactin-inhibiting hormone. Endocr Rev (1985) 1.72
Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci U S A (1989) 1.56
The trkB tyrosine protein kinase is a receptor for neurotrophin-4. Neuron (1992) 1.47
The relationship between serum prolactin and immunocytochemical staining for prolactin in patients with pituitary macroadenomas. Clin Endocrinol (Oxf) (1985) 1.40
Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature (1981) 1.38
Bromocriptine in management of large pituitary tumours. Br Med J (Clin Res Ed) (1982) 1.36
The physiological function of nerve growth factor in the central nervous system: comparison with the periphery. Rev Physiol Biochem Pharmacol (1987) 1.33
Nerve growth factor promotes human hemopoietic colony growth and differentiation. Proc Natl Acad Sci U S A (1988) 1.28
Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab (1981) 1.27
TrkB mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor. Cell (1991) 1.25
IMMUNOLOGY OF SPONTANEOUS MAMMARY CARCINOMAS IN MICE. II. RESISTANCE TO A RAPIDLY AND A SLOWLY DEVELOPING TUMOR. Cancer Res (1965) 1.21
Development of septal cholinergic neurons in culture: plating density and glial cells modulate effects of NGF on survival, fiber growth, and expression of transmitter-specific enzymes. J Neurosci (1988) 1.10
Reduction in size of a pituitary tumor by bromocriptine therapy. N Engl J Med (1979) 1.08
NGF induction of NGF receptor gene expression and cholinergic neuronal hypertrophy within the basal forebrain of the adult rat. Neuron (1989) 1.02
Management of prolactinomas. Clin Endocrinol (Oxf) (1991) 1.01
Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery? JAMA (1982) 0.98
Regulation of muscarinic ligand binding sites by nerve growth factor in PC12 phaeochromocytoma cells. Nature (1982) 0.97
Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab (1989) 0.96
Selective transsphenoidal adenomectomy in women with galactorrhea-amenorrhea. JAMA (1979) 0.96
Dopamine, the dopamine D2 receptor and pituitary tumours. Clin Endocrinol (Oxf) (1991) 0.96
Galactorrhea-amenorrhea syndrome: follow-up of forty-five patients after pituitary tumor removal. Ann Intern Med (1981) 0.86
Absence of high affinity dopamine receptor in GH3 cells: a prolactin-secreting clone resistant to the inhibitory action of dopamine. Endocrinology (1980) 0.86
Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line. Endocrinology (1991) 0.84
Lack of coupling of D-2 receptors to adenylate cyclase in GH-3 cells exposed to epidermal growth factor. Possible role of a differential expression of Gi protein subtypes. J Biol Chem (1991) 0.79
Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med (1985) 0.77
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet (2000) 4.37
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science (1996) 2.52
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A (1995) 2.33
Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab (1995) 2.00
Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A (1994) 1.97
The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A (1996) 1.84
Regulation of the macrophage content of neoplasms by chemoattractants. Science (1983) 1.83
Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry (1997) 1.80
Structure and functional expression of cloned rat serotonin 5HT-2 receptor. EMBO J (1988) 1.74
Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci (1996) 1.70
Non-length-dependent small fibre neuropathy. Confocal microscopy study of the corneal innervation. J Neurol Neurosurg Psychiatry (2010) 1.62
Acromegaly associated with a granular cell tumor of the neurohypophysis: a clinical and histological study. Case report. J Neurosurg (2000) 1.60
Comprehensive critical incident monitoring in a neonatal-pediatric intensive care unit: experience with the system approach. Intensive Care Med (2000) 1.58
HER2 as a prognostic factor in breast cancer. Oncology (2001) 1.43
N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina. Vis Neurosci (1992) 1.42
The fecal microbial population in the irritable bowel syndrome. Microbiologica (1982) 1.40
Alzheimer's disease and Lewy body dementia. Br J Psychiatry (1993) 1.39
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol (2008) 1.31
Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res (1997) 1.29
Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBr1) which specifically binds to human mammary epithelial cells. Cancer Res (1983) 1.16
Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int J Cancer (1984) 1.15
Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer (2006) 1.09
Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol (2004) 1.08
Retinoic acid prevents experimental Cushing syndrome. J Clin Invest (2001) 1.05
Interleukin-1beta and glutamate activate the NF-kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J Biol Chem (1996) 1.05
Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery (2000) 1.05
NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ (2005) 1.04
The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res (2000) 1.02
The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. Endocr Relat Cancer (2005) 1.02
ELISA for toxoplasma antibody detection: a comparison with other serodiagnostic tests. J Clin Pathol (1980) 1.01
CD11b expression identifies CD8+CD28+ T lymphocytes with phenotype and function of both naive/memory and effector cells. J Immunol (2001) 1.01
Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. Eur J Nucl Med (1994) 1.01
Update of the NGF saga. J Neurol Sci (1995) 1.00
Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: evidence for a role in the regulation of the macrophage content of neoplastic tissues. Int J Cancer (1983) 0.99
Proton magnetic resonance spectroscopy and intracranial tumours: clinical perspectives. J Neurol (1996) 0.98
Identification and characterization of a kappa B/Rel binding site in the regulatory region of the amyloid precursor protein gene. J Biol Chem (1995) 0.97
Molecular mechanisms underlying wound healing and anti-inflammatory properties of naturally occurring biotechnologically produced phenylpropanoid glycosides. Cell Mol Biol (Noisy-le-grand) (2007) 0.96
Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol (2012) 0.96
Expression of CD28 on CD8+ and CD4+ lymphocytes during HIV infection. Scand J Immunol (1994) 0.96
Contribution of CD4+, CD8+CD28+, and CD8+CD28- T cells to CD3+ lymphocyte homeostasis during the natural course of HIV-1 infection. J Clin Invest (1998) 0.95
Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res (1996) 0.94
Dopamine receptors on human T- and B-lymphocytes. J Neuroimmunol (1993) 0.94
The detection and biological activity of human antibodies to IL-2 in normal donors. Scand J Immunol (1993) 0.93
Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res (2000) 0.93
Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy. Br J Dermatol (2005) 0.92
Ecophylaxis: preventive treatment with gentamicin of rabbit lincomycin-associated diarrhea. Folia Vet Lat (1978) 0.91
The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells. Int J Cancer (1984) 0.91
Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab (1996) 0.91
Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas. J Endocrinol (2012) 0.90
Bacterial endotoxin (lipopolysaccharide) stimulates interleukin-6 production and inhibits growth of pituitary tumour cells expressing the toll-like receptor 4. J Neuroendocrinol (2005) 0.90
Characterization of T cell subsets involved in the production of IFN-gamma in asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses (1996) 0.90
The desmopressin test in the differential diagnosis between Cushing's disease and pseudo-Cushing states. J Clin Endocrinol Metab (2000) 0.90
Disorders of growth hormone and corticotropin regulation in patients with empty sella. J Neurosurg (1973) 0.90
Inhibition of IkappaBalpha phosphorylation prevents glutamate-induced NF-kappaB activation and neuronal cell death. Acta Neurochir Suppl (2005) 0.89
Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab (2001) 0.88
Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Proc Natl Acad Sci U S A (1996) 0.88
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol (2008) 0.88
Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats. Lab Invest (1996) 0.88
Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. Endocrinology (1994) 0.88
Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas. Am J Pathol (2000) 0.87
The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury. Cell Death Dis (2010) 0.87
Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study. Cancer Immunol Immunother (1986) 0.87
Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment. Prostate (1997) 0.87
[Combined neuronal and endocrine tumors of the sellar region]. Pathologe (1997) 0.86
Systemic administration of insulin-like growth factor decreases motor neuron cell death and promotes muscle reinnervation. J Neurosci Res (1998) 0.86
Choline acetyltransferase messenger RNA expression in developing and adult rat brain: regulation by nerve growth factor. Brain Res Mol Brain Res (1991) 0.86
Dopamine D2, D3, and D4 receptor mRNA levels in rat brain and pituitary during aging. Neurobiol Aging (1995) 0.86
Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab (2005) 0.86
Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine. Proc Natl Acad Sci U S A (1992) 0.86
Segregation of type 1 cytokine production in human peripheral blood lymphocytes: phenotypic differences between IFN-gamma and IL-2-producing cells in the CD8+ T cell subset. Eur J Immunol (1998) 0.86
Glycosaminoglycans boost insulin-like growth factor-I-promoted neuroprotection: blockade of motor neuron death in the wobbler mouse. Neuroscience (1999) 0.86
Sellar and parasellar extra-axial cavernous hemangiomas. Acta Neurochir (Wien) (1994) 0.86
Microplate enzyme-linked immunosorbent assay for bovine leukemia virus antibody. J Clin Microbiol (1981) 0.86
mGluR5 metabotropic glutamate receptor distribution in rat and human spinal cord: a developmental study. Neurosci Res (1997) 0.85
Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease. Clin Endocrinol (Oxf) (2001) 0.85
Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines. Clin Cancer Res (1999) 0.85
RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells. Endocr Relat Cancer (2012) 0.85
Induction of tumour-suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurones triggered by excitatory amino acids. Eur J Neurosci (1998) 0.85
Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J Clin Endocrinol Metab (1998) 0.85
Activation of NF-kappaB p65/c-Rel dimer is associated with neuroprotection elicited by mGlu5 receptor agonists against MPP(+) toxicity in SK-N-SH cells. J Neural Transm (Vienna) (2007) 0.85
Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. Eur J Pharmacol (1997) 0.84
Identification of novel alternatively-spliced mRNA isoforms of metabotropic glutamate receptor 6 gene in rat and human retina. Gene (2001) 0.84
Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology (2001) 0.84
Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line. Endocrinology (1991) 0.84
Effect of serotonin and nicotine on the growth of a human small cell lung cancer xenograft. Anticancer Res (1997) 0.84
Coexistence of TSH-secreting pituitary adenoma and autoimmune hypothyroidism. J Endocrinol Invest (2006) 0.84
Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells? Clin Endocrinol (Oxf) (1998) 0.84
Mechanisms of chromium toxicity in mammalian cell cultures. Toxicology (1980) 0.84
Subtypes of beta-adrenergic receptors in rat cerebral microvessels. Brain Res (1981) 0.83
Cytogenetic study of pituitary adenomas. Cancer Genet Cytogenet (1997) 0.83